Naples, Florida – Stemtech Corporation (OTCID: STEK), a pioneer in stem cell nutrition and plant-based wellness products, has appointed Alejandro Carrillo as President of Latin Markets. The appointment took effect immediately. Carrillo previously served as Vice President of Global Sales.
This move strengthens leadership in the company’s strongest-performing region. Latin America, including the Hispanic population in the United States, remains a key growth driver for Stemtech.
Carrillo joined Stemtech in 2015 as General Manager of Stemtech Mexico. Under his leadership, Mexico grew into the company’s largest and most consistent market. His success led to broader roles overseeing Latin Markets and later global sales.
In March 2025, he became Vice President of Global Operations. In that role, he focused on manufacturing, inventory, and international expansion. He brings more than 18 years of experience in network marketing. customer service.
His career began in banking after earning an MBA. Since 2008, he has focused on multi-level marketing, emphasizing product quality, innovation, and
Charles S. Arnold, Chairman and CEO of Stemtech, said: “Alejandro has done exactly what we hoped a great market leader would do. He took Mexico to become our anchor market, and then he helped bring that same discipline to our global sales organization. Appointing him to President, Latin Markets is a natural next step.”
John W. Meyer, President and COO, added: “Latin America, including the significant Hispanic population in the United States, has been the heartbeat of this company’s growth, and Alejandro is the reason for that. This appointment is a commitment to giving him the mandate to do even more.”
Stemtech traces its roots to 2005, when Stemtech International, Inc. launched as a pioneer in adult stem cell nutrition. The company developed plant-based supplements designed to support the body’s natural regenerative processes. From 2010 to 2015, the predecessor company appeared four times on the Inc. 5000 list of fastest-growing private companies.
In 2018, the company underwent major restructuring and new ownership. Operations continued under Stemtech Corporation. Charles S. Arnold and John W. Meyer took key leadership roles. In August 2021, Stemtech became publicly traded under the ticker STEK through a reverse merger.
The company uses a direct-selling model with Independent Business Partners (IBPs). It operates in North America, Latin America, and Asia, with recent expansion efforts in India, Taiwan, and other markets.
Stemtech is a publicly traded company on the OTC markets. Key executives and directors hold significant shares. Charles S. Arnold serves as Chairman and CEO. He has a background in finance, marketing, and public company investments. He has helped place more than $1 billion into various companies and was an early investor in Pre-Paid Legal (now LegalShield).
John W. Meyer is President, COO, and a director. He joined the company in 2006. He has overseen operations and helped open dozens of national markets. Meyer previously worked at network marketing firms including Shaklee and Arbonne, as well as in logistics for Fortune 100 companies. He holds degrees from the University of San Francisco.
Other board members have included John Thatch, Benjamin Kaplan, and Darryl V. Green. Srilakshmi Vadlapatla serves as CFO. The board and named executives collectively hold a substantial ownership stake.
Stemtech specializes in “stemceuticals” — all-natural, plant-based products that support adult stem cell physiology. The flagship RCM System includes three key products:
Additional products include:
All products use plant-based, non-GMO ingredients and contain no actual stem cells. The company positions them as support for natural regenerative processes, healthy aging, and overall vitality.
Carrillo’s appointment signals continued focus on Latin America as a core growth engine. Stemtech aims to expand its distributor network, strengthen marketing, and introduce products across wellness, oral care, skin care, and pet health categories. The company continues to emphasize scientific innovation and natural approaches to cellular health and longevity.
For more information, visit the official Stemtech website or follow company updates on its public filings and press releases.
There are no reviews yet. Be the first one to write one.
